PAR Engages NBCD to Expand P3 Global Footprint

Paradigm Biopharmaceuticals Ltd. has engaged NBCD A/S to expand its global Phase 3 footprint, adding four new high-performing clinical sites in Hong Kong and Moldova. This partnership will enhance the ongoing pivotal Phase 3 knee osteoarthritis trial by strengthening data robustness and geographic reach. The inclusion of these sites aligns with Paradigm's goal of maintaining commercial readiness and timeline management.<br/><br/>Establishing a clinical presence in Hong Kong will support future regulatory and commercial opportunities, while the Moldova sites offer access to experienced investigators and a diverse patient population suited for OA studies. Screening and recruitment across active sites are progressing well, with the interim analysis set for mid-2026 as planned.<br/><br/>Investors are encouraged to reach out with any questions regarding this development. Paradigm remains committed to delivering new therapies to address unmet medical needs and improving patients' health and quality of life. For more information, please visit our website at investors.paradigmbiopharma.com.